Stratatech Awarded $47.2 Million Government Contract for Burn Therapy
Stratatech Corporation has been awarded a contract valued at up to $47.2 million by the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA).
The five-year contract supports preclinical, clinical, regulatory, and technology development activities for StrataGraft skin tissue as a treatment for severe burns.
The company was founded in 2000 by B. Lynn Allen-Hoffmann, PhD, professor in the Department of Pathology and Laboratory Medicine at the University of Wisconsin School of Medicine and Public Health and Stratatech's chief executive and chief scientific officer.
StrataGraft skin tissue is a viable, full-thickness skin substitute designed to mimic natural human skin. Stratatech’s product lines, including StrataGraft skin tissue, use NIKS human keratinocyte progenitors. NIKS cells were initially isolated and characterized in the laboratory of Dr. Allen-Hoffmann at the University of Wisconsin School of Medicine and Public Health.
The BARDA contract advances this Department of Pathology and Laboratory Medicine discovery to late stage clinical trials, supporting activities required for FDA approval of StrataGraft skin tissue in the treatment of thermal burn injuries.
Date Published: 08/15/2013